Aquilab SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aquilab SAS - overview
Location
Caubios-loos, -, France
Primary Industry
Software
About
Based in Loos, France, Aquilab Sas, operates as a healthcare technology company that offers software solutions for diagnostic imaging and radiotherapy treatments. The company was founded by its CEO David Gibon. In April 2022, Coexya, a portfolio company of Argos Wityu, acquired Aquilab SAS. As of 2022, the company consists of 25 employees and has a product reach in 60 countries with 3300 users on Onco Place.
The products and services offered by the firm help in quality assurance and offer evaluation software for medical imaging and radiotherapy. The company offers Artiscan, which is a software platform that offers complete and automatic imaging and machine QA in radiation oncology, imaging, and nuclear medicine it is compatible with all phantoms and is a three-step automatic procedure. A collaborative solution is also offered by the company for plan preparation and helps in evaluating radiology treatments known as Artiview. Oneplace is also another offering by the firm which is a web-based platform for reviewing images, management of the clinical trial,s and RT treatment review.
Aquilab is also a certified training organization and has its own training courses.
Current Investors
Coexya
Primary Industry
Software
Sub Industries
Healthcare IT, Oncology/Cancer Treatment, Medical Devices & Equipment, Medical Software
Website
www.aquilab.com
Verticals
HealthTech, Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Aquilab SAS - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 1,562,357 | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | 582,754 | - | - | - | - | - |
| Operating Income (USD) | (150,947) | - | - | - | - | - |
| Operating Margin | (9.7%) | - | - | - | - | - |
| % EBITDA Margin | 37.3% | - | - | - | - | - |
| NET Income (USD) | (68,938) | - | - | - | - | - |
| % Net Margin | (4.4%) | - | - | - | - | - |
Aquilab SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Aquilab SAS | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.